% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sahm:143136,
      author       = {F. Sahm$^*$ and D. E. Reuss$^*$ and C. Giannini},
      title        = {{WHO} 2016 classification: changes and advancements in the
                      diagnosis of miscellaneous primary {CNS} tumours.},
      journal      = {Neuropathology $\&$ applied neurobiology},
      volume       = {44},
      number       = {2},
      issn         = {0305-1846},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2019-00745},
      pages        = {163 - 171},
      year         = {2018},
      abstract     = {This short review highlights significant changes and recent
                      findings incorporated to varying extent in the WHO 2016
                      definition of a variety of tumours, including peripheral
                      nerve sheath tumours, meningiomas, mesenchymal
                      nonmeningothelial tumours, melanocytic tumours, lymphomas
                      and histiocytic tumours, germ cell tumours and
                      non-neuroendocrine pituitary tumours. Most notable
                      classification changes include: adding hybrid nerve sheath
                      tumours to the spectrum of benign nerve sheath tumours; an
                      updated definition of atypical meningioma (WHO grade II),
                      including cases with brain invasion; recognizing dural
                      solitary fibrous tumour (SFT) and haemangiopericytoma (HPC)
                      as a single tumour entity characterized by NAB2 and STAT6
                      gene fusions for which the term SFT/HPC was chosen;
                      recognizing that pituitary granular cell tumour, spindle
                      cell oncocytoma, and pituicytoma all share nuclear
                      expression of TTF-1, possibly representing a spectrum of a
                      single nosological entity derived from posterior pituitary
                      glial cells. The most significant diagnostic markers which
                      have emerged include: inactivation of NF1, CDKN2A, and PRC2
                      components, SUZ12 and EED in MPNST, leading to neurofibromin
                      and H3K27me3 expression loss; GNAQ and GNA11 mutations in
                      CNS primary melanocytic tumours; BRAFV600E mutation in
                      histiocytic tumours (Langerhans cell histiocytosis and
                      Erdheim-Chester disease) and papillary craniopharyngioma,
                      which provides both a diagnostic marker in the appropriate
                      pathological setting and a therapeutic target. The WHO 2016
                      Classification has balanced cutting-edge knowledge on the
                      molecular characteristics of the miscellaneous CNS tumours
                      reviewed here with a practical approach for their daily
                      diagnostic work-up. Much more progress can be expected in
                      the classification of these neoplasms in the near future.},
      subtyp        = {Review Article},
      cin          = {G380},
      ddc          = {610},
      cid          = {I:(DE-He78)G380-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28295484},
      doi          = {10.1111/nan.12397},
      url          = {https://inrepo02.dkfz.de/record/143136},
}